NEW: World Trade TARIFFS Simulator!
NEW: 2023 Data and Complexity Rankings
Sign In
Pricing

Human blood; animal blood for therapeutic, prophylactic or diagnostic uses; antisera, other blood fractions, immunological products, modified or obtained by biotechnological processes; vaccines, toxins, cultures of micro-organisms (excluding yeasts) etc

3002 (Harmonized System 1992 for 4-digit)

2023
World Trade $334BRnk 10 / 1217
2023
Top Exporter | Top Importer $52.2B | $79.7BUnited States | United States
2023
Product Complexity 1.2Rnk 106 / 1044
2022 - 2023
Export Growth (CAGR) 0.27%Rnk 398 / 1217
2023
Share of World Trade 1.48%Rnk 10 / 1217

About

Overview This page contains the latest trade data of Vaccines, blood, antisera, toxins and cultures. In 2023, Vaccines, blood, antisera, toxins and cultures were the world's 10th most traded product, with a total trade of $334B. Between 2022 and 2023 the exports of Vaccines, blood, antisera, toxins and cultures grew by 0.27%, from $333B to $334B. Trade in Vaccines, blood, antisera, toxins and cultures represent 1.48% of total world trade.

Vaccines, blood, antisera, toxins and cultures are a part of Pharmaceutical products. They include Antisera and other blood fractions, Blood, toxins, cultures, medical use, nes, Vaccines, human use, Vaccines, veterinary use, except foot and mouth, and Vaccines, foot and mouth disease, veterinary use.

Exports In 2023 the top exporters of Vaccines, blood, antisera, toxins and cultures  were United States ($52.2B), Ireland ($51.3B), Germany ($43.5B), Switzerland ($39.4B), and Belgium ($28.1B).

Imports In 2023 the top importers of Vaccines, blood, antisera, toxins and cultures were United States ($79.7B), Germany ($36.1B), Belgium ($26.3B), China ($19.8B), and Switzerland ($17.5B).

Ranking Vaccines, blood, antisera, toxins and cultures ranks 106th in the Product Complexity Index (PCI).

Description Human blood is used to provide oxygen and nutrients to the tissues and to carry away waste products from the tissues. Animal blood prepared for therapeutic, prophylactic or diagnostic uses is used to study blood-borne diseases and to provide antibodies that are used in the diagnosis of diseases. Antisera and other blood fractions and immunological products, whether or not modified or obtained by means of biotechnological processes, are used in the diagnosis of diseases. Vaccines, toxins, cultures of micro-organisms (excl. yeasts) and similar products are used in the prevention and treatment of diseases.

Latest Trends

Latest Data

View
Flow
Y-AXIS SCALE

The following visualization shows the latest trends on Vaccines, blood, antisera, toxins and cultures. Countries are shown based on data availability.

For a full breakdown of trade patterns, visit the trend explorer or the product in country profile.

Explore Latest Trends

* Trade values are converted to USD using each month's exchange rate. For December 2023 data, the exchange rate from December 30, 2023 is used.

Subscribe today to OEC pro and access the latest data

Sign Up

Historical Data

Exporters and Importers

Top Origin (2023)United States$52.2B
Top Destination (2023)United States$79.7B

In 2023 Vaccines, blood, antisera, toxins and cultures were the world's 10th most traded product (out of 1,217).

In 2023, the top exporters of Vaccines, blood, antisera, toxins and cultures were United States ($52.2B), Ireland ($51.3B), Germany ($43.5B), Switzerland ($39.4B), and Belgium ($28.1B).

In 2023, the top importers of Vaccines, blood, antisera, toxins and cultures were United States ($79.7B), Germany ($36.1B), Belgium ($26.3B), China ($19.8B), and Switzerland ($17.5B).

Explore Visualizations

Exporters of Vaccines, blood, antisera, toxins and cultures (2023)
[Click to Select a Country]

Importers of Vaccines, blood, antisera, toxins and cultures (2023)
[Click to Select a Country]

Market Dynamics

Color
Top Origin Growth (2022 -  2023)Singapore$6.02B
Top Destination Growth (2022 -  2023)United States$13.2B

Between 2022 and 2023, the exports of Vaccines, blood, antisera, toxins and cultures grew the fastest in Singapore ($6.02B), Netherlands ($5.98B), Ireland ($4.21B), Switzerland ($3.57B), and United States ($2.03B).

Between 2022 and 2023, the fastest growing importers of Vaccines, blood, antisera, toxins and cultures were United States ($13.2B), Belgium ($4.12B), France ($3.26B), China ($3.22B), and Netherlands ($2.63B).

Explore Visualizations

Exporters of Vaccines, blood, antisera, toxins and cultures (2022 - 2023)

Importers of Vaccines, blood, antisera, toxins and cultures (2022 - 2023)

Market Concentration

Value

This chart shows the evolution of the market concentration of exports of Vaccines, blood, antisera, toxins and cultures.

In 2023, market concentration measured using Shannon Entropy, was 3.84. This means that most of the exports of Vaccines, blood, antisera, toxins and cultures are explained by 14 countries.

Explore Visualizations

Value of Exports in Vaccines, blood, antisera, toxins and cultures

Net Trade

TOP NET EXPORTER (2023)Ireland$44.4B
TOP NET IMPORTER (2023)United States$27.6B

This map shows which countries export or import more of Vaccines, blood, antisera, toxins and cultures. Each country is colored based on the difference in exports and imports of Vaccines, blood, antisera, toxins and cultures during 2023.

In 2023, the countries that had a largest trade value in exports than in imports of Vaccines, blood, antisera, toxins and cultures were Ireland ($44.4B), Switzerland ($21.9B), Netherlands ($12.7B), Singapore ($9.43B), and Germany ($7.37B).

In 2023, the countries that had a largest trade value in imports than in exports of Vaccines, blood, antisera, toxins and cultures were United States ($27.6B), China ($18.3B), Japan ($7.28B), Canada ($5.62B), and France ($5.32B).

Net Trade (2023)

Disaggregation

Value

In 2023, the world most traded Vaccines, blood, antisera, toxins and cultures, disaggragated by their HS6 level were Blood, toxins, cultures, medical use, nes ($258B), Vaccines, human use ($58B), Antisera and other blood fractions ($13.2B), and Vaccines, veterinary use, except foot and... ($5.01B)

HS6 Disaggregation for Vaccines, blood, antisera, toxins and cultures (2023)
[Click to Select]

Country Comparison

Flow
Measure
Ranking

This visualization shows the countries that have an important ratio of their trade related to Vaccines, blood, antisera, toxins and cultures.
It is possible to select the main countries that export or import Vaccines, blood, antisera, toxins and cultures in the world, or by continent, as well as select the measure of interest.

Top 10 Exporters Countries of Vaccines, blood, antisera, toxins and cultures by percentage of total exports

Potential Exports

Potential Exports

Flow
View
TOP EXPORT POTENTIALUnited Kingdom+ $503M
TOP IMPORT POTENTIALGermany+ $168M

Vaccines, blood, antisera, toxins and cultures’s highest export potential is United Kingdom. With an export gap of $503M.  Vaccines, blood, antisera, toxins and cultures’s highest import potential is Germany with an import gap of $168M.

See methodology.

Subscribe today to OEC pro and access the latest data

Sign Up

Product Complexity

Diversification Frontier

Specialization

The Complexity-Relatedness diagram compares the risk and the strategic value of a product's potential export opportunities. Relatedness is predictive of the probability that a country increases its exports in a product. Complexity, is associated with higher levels of income, economic growth potential, lower income inequality, and lower emissions.

Relatedness vs Country Complexity (2023)

Related Products

This visualization shows products that are likely to be exported by countries that export Vaccines, blood, antisera, toxins and cultures.

Country by Relatedness

The following visualization shows the relatedness of Vaccines, blood, antisera, toxins and cultures to countries. Higher relatedness values ​​indicate greater knowledge, which predicts a greater probability of exporting that product in the future.

Relative Relatedness by Country (2023)

Keep Exploring

Have questions, comments, or concerns?
Send us an e-mail: support@oec.world
Follow @OECtoday on
Created, Designed, and Developed by:
In collaboration with
About the OECPrivacy PolicyTerms